Historical treatment of chronic hepatitis B and C TABLE III Antiviral
نویسندگان
چکیده
Correspondence to: Dr P Ferenci, Clinic of Internal Medicine IV, Department of Gastroenterology and Hepatology, University of Vienna, Wahringer Gurtel 18-20, A-1090 Wien, Austria. Abstract Interferon is currently considered to be the only accepted effective treatment for chronic viral hepatitis. A history of the treatment of chronic hepatitis B and C before the use of interferon is presented here. Hepatitis B virus does not seem to be directly cytopathic and the disease is known to be modulated largely by the host's immune response. Experience with immunosuppressant and immunostimulant drugs and a wide variety of antiviral agents, however, has indicated that none of these are of any benefit in patients with chronic hepatitis B, with the possible exception ofadenine arabinoside. In view of the much more recent identification of the hepatitis C virus, studies of therapy for chronic hepatitis C are inevitably less extensive. A pilot study using acyclovir in patients with chronic non-A, non-B hepatitis did not show any benefit, although the treatment period may have been too short for the results to be conclusive. The only agent other than alpha interferon to be tried in chronic hepatitis C is ribavirin, which may have some activity. Many of the agents studied in chronic hepatitis B should also be investigated for the treatment of patients with chronic hepatitis C. (Gut 1993; supplement: S69-S73)
منابع مشابه
Frequency of YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines
Abstract Background: Investigators were suspicious of tyrosine-methionine-aspartate-aspartate (YMDD) mutations occurred only in patients who were treated by lamivudine. However, YMDD mutations of hepatitis B virus gene (HBV DNA) in patients with chronic hepatitis B (CHB) untreated with antiviral medicines was reported in some studies. The aim of this study was to evaluate YMDD mutations in Ira...
متن کاملSeroprevalence of Hepatitis B and C Virus Infection in Children with Chronic Kidney Diseases; A Historical Cohort Study
Background: The prevalence of hepatitis B and C in Iranian children with chronic kidney disease is limited. Therefore, the present study intends to assess the prevalence of hepatitis B and C in children with chronic kidney disease (CKD).Method: The present study is a historical cohort study which was conducted in a window period of 25 years in Children’s Medical Center in Tehran, 1991-2016. Dat...
متن کاملNew treatment of hepatitis C (Direct Acting Antiviral)
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for the patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy an...
متن کاملبررسی عوامل مرتبط با شدت فیبروز کبد در بیماران مبتلا به هپاتیتهای مزمن B و C
Background & Aim: Viral hepatitis has existed since the creation of human. The estimated prevalence of hepatitis is about 3-5%. For patients with chronic hepatitis C and moderate to severe liver fibrosis, antiviral therapy is strongly suggested, while the cases without fibrosis or with mild liver fibrosis are often followed up without receiving antiviral therapy. The purpose of the present s...
متن کاملVitiligo Complicating chronic Hepatitis B patients treated with α-Interferon (Report of two cases)
α-Interferon is an antiviral agent used in treatment of chronic hepatitis B. Triggering of the underlying autoimmune disease or exacerbation of pre-existing auto immune disease is documented with α-interferon, but there are few reports about occurrence of autoimmune disorders such as systemic lupus erythematosus, Vitiligo, hypo and hyperthyroidism after administration of α-interferon in the lit...
متن کامل